R Squared’s Cellebrite CLBT Stock Holding History

R Squared’s Portfolio CLBT Stock Details CLBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-11,837	Closed	-$189K	–	580
2025 Q2	$189K	Buy	+11,837	New	+$211K	0.1%	312
2025 Q1	–	Sell	-4,530	Closed	-$99.8K	–	535
2024 Q4	$99.8K	Buy	+4,530	New	+$87.2K	0.1%	260

Other funds holding CLBT

TWCM

True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Axon Enterprise Scottsdale, Arizona $19.1M AUM 8.75% 1-Year Est. Return

CCPM

Cooper Creek Partners Management New York $4.21B AUM 44.81% 1-Year Est. Return

R Squared's CLBT Position: Q3 2025 in Review

R Squared sold out of Cellebrite (CLBT) in Q3 2025, closing a stake of 11,837 shares — an estimated $189K sold.

R Squared first reported a position in CLBT in Q4 2024 and held it in 2 quarters. The position peaked at $189K in Q2 2025. 197 funds tracked by Wall St. Rank hold CLBT as of Q3 2025.

R Squared reported no remaining Cellebrite position as of Q3 2025 after selling out during the quarter.
R Squared sold 11,837 Cellebrite shares in Q3 2025, an estimated $189K.
R Squared first reported a position in Cellebrite in Q4 2024 and held it in 2 quarters.
R Squared's Cellebrite position peaked at $189K in Q2 2025.
197 funds tracked by Wall St. Rank held Cellebrite as of Q3 2025.

Based on R Squared's 13F filing for Q3 2025, filed 12 Nov 2025.